Literature DB >> 16027766

The relation between body fat distribution and cardiovascular risk factors in patients with schizophrenia: a cross-sectional pilot study.

Martha M Kato1, M Beatriz Currier, Oscar Villaverde, Mercedes Gonzalez-Blanco.   

Abstract

BACKGROUND: Obesity has recently become a concern for physicians treating schizophrenic patients. Obesity is associated with hypertension, dyslipidemia, and diabetes mellitus. In this pilot study, we investigate which anthropometric measurement, body mass index or waist circumference, is a better predictor of cardiovascular risk factors in patients with schizophrenia.
METHOD: This cross-sectional study, conducted from January 2001 to January 2002, examined body fat distribution and its relation to cardiovascular risk factors in 62 patients with schizophrenia (DSM-IV) recruited from an outpatient psychiatric clinic.
RESULTS: Chi-square analysis revealed that an increased waist circumference was associated with dyslipidemia (p < .01), hypertension (p < .05), and abnormal serum glucose (p < .05), whereas an increased body mass index was only associated with dyslipidemia (p < .05). In logistic regression analysis, after controlling for age, gender, race, ethnicity, smoking, and body mass index, increased waist circumference remained significantly associated with dyslipidemia (odds ratio = 2.08, 95% CI = 1.01 to 1.15, p < .05) and hypertension (odds ratio = 2.05, 95% CI = 1.02 to 1.17, p < .05).
CONCLUSIONS: Waist circumference revealed a stronger correlation than body mass index to cardiovascular risk factors in patients with schizophrenia. We propose the measurement of waist circumference as a screening tool for cardiovascular risk factors in this population. Waist circumference measurement can provide an opportunity for primary prevention of coronary heart disease and diabetes mellitus in patients with schizophrenia.

Entities:  

Year:  2005        PMID: 16027766      PMCID: PMC1163272          DOI: 10.4088/pcc.v07n0307

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN: 1523-5998


  14 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  Basic and clinical aspects of regional fat distribution.

Authors:  C Bouchard; G A Bray; V S Hubbard
Journal:  Am J Clin Nutr       Date:  1990-11       Impact factor: 7.045

Review 3.  Antipsychotic-induced weight gain: a comprehensive research synthesis.

Authors:  D B Allison; J L Mentore; M Heo; L P Chandler; J C Cappelleri; M C Infante; P J Weiden
Journal:  Am J Psychiatry       Date:  1999-11       Impact factor: 18.112

4.  Weight gain associated with antipsychotic drugs.

Authors:  R Ganguli
Journal:  J Clin Psychiatry       Date:  1999       Impact factor: 4.384

5.  Novel antipsychotics: comparison of weight gain liabilities.

Authors:  D A Wirshing; W C Wirshing; L Kysar; M A Berisford; D Goldstein; J Pashdag; J Mintz; S R Marder
Journal:  J Clin Psychiatry       Date:  1999-06       Impact factor: 4.384

6.  Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913.

Authors:  B Larsson; K Svärdsudd; L Welin; L Wilhelmsen; P Björntorp; G Tibblin
Journal:  Br Med J (Clin Res Ed)       Date:  1984-05-12

7.  Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden.

Authors:  L Lapidus; C Bengtsson; B Larsson; K Pennert; E Rybo; L Sjöström
Journal:  Br Med J (Clin Res Ed)       Date:  1984-11-10

8.  Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample.

Authors:  T S Han; E M van Leer; J C Seidell; M E Lean
Journal:  BMJ       Date:  1995-11-25

9.  Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in a general population. Atherosclerosis Risk in Communities Study Investigators.

Authors:  M I Schmidt; R L Watson; B B Duncan; P Metcalf; F L Brancati; A R Sharrett; C E Davis; G Heiss
Journal:  Metabolism       Date:  1996-06       Impact factor: 8.694

Review 10.  Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults.

Authors: 
Journal:  Arch Intern Med       Date:  1998-09-28
View more
  5 in total

1.  Racial patterns of cardiovascular disease risk factors in serious mental illness and the overall U.S. population.

Authors:  Tanya E Keenan; Airong Yu; Lisa A Cooper; Lawrence J Appel; Eliseo Guallar; Joseph V Gennusa; Faith B Dickerson; Rosa M Crum; Cheryl A Anderson; Leslie M Campbell; Deborah R Young; Gail L Daumit
Journal:  Schizophr Res       Date:  2013-07-31       Impact factor: 4.939

2.  Olanzapine, weight change and metabolic effects: a naturalistic 12-month follow up.

Authors:  Marina Salviato Balbão; Jaime Eduardo Cecílio Hallak; Emerson Arcoverde Nunes; Mauricio Homem de Mello; Andresa de Toledo Triffoni-Melo; Flavia Isaura de Santi Ferreira; Cristiano Chaves; Ana Maria Sertori Durão; Adriana Pelegrino Pinho Ramos; José Alexandre de Souza Crippa; Regina Helena Costa Queiroz
Journal:  Ther Adv Psychopharmacol       Date:  2014-02

3.  Waist circumference, body mass index, and their association with cardiometabolic and global risk.

Authors:  Allison H Christian; Heidi Mochari; Lori J Mosca
Journal:  J Cardiometab Syndr       Date:  2009

4.  High Prevalence of Obesity, Hypertension, Hyperlipidemia, and Diabetes Mellitus in Japanese Outpatients with Schizophrenia: A Nationwide Survey.

Authors:  Takuro Sugai; Yutaro Suzuki; Manabu Yamazaki; Kazutaka Shimoda; Takao Mori; Yuji Ozeki; Hiroshi Matsuda; Norio Sugawara; Norio Yasui-Furukori; Yoshitake Minami; Kurefu Okamoto; Toyoaki Sagae; Toshiyuki Someya
Journal:  PLoS One       Date:  2016-11-17       Impact factor: 3.240

5.  Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia.

Authors:  Krithika Rajagopalan; David Trueman; Lydia Crowe; Daniel Squirrell; Antony Loebel
Journal:  Pharmacoeconomics       Date:  2016-07       Impact factor: 4.981

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.